Compare WEX & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEX | LGND |
|---|---|---|
| Founded | 1983 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 6.0B |
| IPO Year | 2004 | 1997 |
| Metric | WEX | LGND |
|---|---|---|
| Price | $197.77 | $305.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 11 |
| Target Price | $195.36 | ★ $344.25 |
| AVG Volume (30 Days) | ★ 461.0K | 196.3K |
| Earning Date | 10-28-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 12.93 | ★ 2886.36 |
| EPS | ★ 5.33 | 1.63 |
| Revenue | ★ $2,660,800,000.00 | $141,102,000.00 |
| Revenue This Year | $8.92 | $8.04 |
| Revenue Next Year | $1.57 | $31.71 |
| P/E Ratio | ★ $37.18 | $188.34 |
| Revenue Growth | 1.24 | ★ 29.48 |
| 52 Week Low | $125.29 | $175.89 |
| 52 Week High | $203.99 | $326.63 |
| Indicator | WEX | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 69.70 | 54.61 |
| Support Level | $183.52 | $277.97 |
| Resistance Level | $203.97 | $318.30 |
| Average True Range (ATR) | 4.68 | 11.25 |
| MACD | 3.16 | 0.38 |
| Stochastic Oscillator | 96.34 | 69.08 |
WEX Inc is a commerce platform that provides seamlessly embedded, personalized payments solutions. The company operates three business segments: Mobility, Benefits, and Corporate Payments. Mobility segment, the top segment by revenue, provides fleet vehicle payment solutions, transaction processing, and information management services for commercial and government fleets. The Corporate Payments segment offers business-to-business payment processing and transaction monitoring services. The Benefits segment generates revenue from healthcare payment products and its consumer-directed software platform. Its prime end market is the United States of America.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.